Humanwell Healthcare (Group) Co. Ltd. has synthesized prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) and EP4 antagonists reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and cardiovascular diseases.

Researchers at Bioventures LLC and Yale University have disclosed dual inhibitors of bromodomain-containing protein 4 (BRD4; HUNK1) and histone deacetylase (HDAC) reported to be useful for the treatment of cancer and psoriasis.

JS Innomed Holdings Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, renal and cardiovascular disorders.

Entheogenix Biosciences Inc. has described 5-HT2A receptor agonists reported to be useful for the treatment of post-traumatic stress, depression and anxiety disorders.

Genesis Therapeutics Inc. has synthesized CDK2/cyclin A2 inhibitors reported to be useful for the treatment of cancer.

Captor Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to an induced myeloid leukemia cell differentiation protein MCL-1-targeting moiety through a linker.

Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.

Senya Pharmaceuticals Inc. has described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurological disorders.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has divulged myeloperoxidase inhibitors reported to be useful for the treatment of cardiovascular disorders.

SK Biopharmaceuticals Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.